EGFR and neoplasm: AZD9291 is the first novel and irreversible third-generation anti-EGFR agent that shows higher efficacy than other EGFR inhibitors in suppressing GBM cell activity and prolonging the life of mice with orthotopic tumor grafts of GBM [141].